The purpose of this research is to determine which medication provides better and safer conditions for placing the breathing tube in adult patients who need tracheal intubation during surgery. The study will look at how well each medication works and any possible side effects that may occur during or after the procedure.

During the study, patients will receive either remifentanil or rocuronium before the breathing tube is inserted. Doctors will monitor patients for any complications that might occur within 24 hours after the procedure, including effects on breathing, heart function, or discomfort in the throat. The medication doses are carefully calculated based on each patient’s weight, with remifentanil given at up to 4 micrograms per kilogram and rocuronium at up to 0.6 milligrams per kilogram.

The trial will use remifentanil, a medication given through an injection, to see how well it works in providing the right conditions for intubation. Another solution, sodium chloride, will be used to help with the administration of the medication. The study will observe how the babies respond to the medication, focusing on how well they are sedated and how smoothly the intubation process goes. The researchers will also monitor for any side effects, such as changes in heart rate or breathing, to ensure the safety of the newborns.

The study aims to determine the best dose of remifentanil for newborns, both those born at full term and those born prematurely, to ensure the procedure is as safe and effective as possible. The researchers will assess the level of sedation by gently stimulating the baby’s foot and observing their response. The trial will also look at how quickly the babies recover their normal breathing after the procedure and check for any other health concerns that might arise. This research is important for improving the care and comfort of newborns who need this critical medical procedure.